Sign In
Buy SPRB
$42.83
-0.540 (-1.25%)
At Close: Jul 31, 2026
The Schall Law Firm Initiates Investigation Into Spruce Biosciences Inc And Urges Investors With Losses To Connect
11:00am, Saturday, 22'nd Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
The Schall Law Firm Begins Probe Into Spruce Biosciences Inc And Encourages Investors With Losses To Reach Out
05:00pm, Friday, 21'st Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
The Schall Law Firm Initiates Investigation Into Spruce Biosciences Inc And Urges Investors With Losses To Make Contact
04:15pm, Thursday, 20'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
The Schall Law Firm Is Conducting A Probe Into Spruce Biosciences Inc They Encourage Investors Who Have Incurred Losses To Reach Out
04:30pm, Wednesday, 19'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences
Spruce Biosciences, Inc. Is Being Probed By The Schall Law Firm: Investors Who Have Suffered Losses Are Urged To Make Contact
01:00pm, Thursday, 06'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences
Spruce Biosciences Recognized as a Bay Area Best Place to Work
08:00am, Thursday, 06'th Jun 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine an
Spruce Biosciences, Inc. Under Investigation by Schall Law Firm: Investors with Losses Encouraged to Reach Out
01:30pm, Wednesday, 05'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
07:00am, Tuesday, 04'th Jun 2024
SOUTH SAN FRANCISCO, Calif. & MUNICH--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel th
